HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Reaction

Lithium hydroxide, monohydrate → 6-[(4-tert-Butylphenyl)sulfonyl]-7-methyl-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine-8-carboxamide

HRID 1691471
Print

Reaction equation

HRID 1691471 reaction equation
[C:1]([C:3]1[CH:4]=[CH:5][C:6]2[NH:12][C:11]3[N:13]=[C:14]([C:17]([F:20])([F:19])[F:18])[CH:15]=[CH:16][C:10]=3[CH2:9][N:8]([S:21]([C:24]3[CH:29]=[CH:28][C:27]([C:30]([CH3:33])([CH3:32])[CH3:31])=[CH:26][CH:25]=3)(=[O:23])=[O:22])[C:7]=2[C:34]=1[CH3:35])#[N:2].O.[OH-].[Li+].[O:39]1CCOCC1.O>CCOC(C)=O>[C:30]([C:27]1[CH:28]=[CH:29][C:24]([S:21]([N:8]2[C:7]3[C:34]([CH3:35])=[C:3]([C:1]([NH2:2])=[O:39])[CH:4]=[CH:5][C:6]=3[NH:12][C:11]3[N:13]=[C:14]([C:17]([F:19])([F:20])[F:18])[CH:15]=[CH:16][C:10]=3[CH2:9]2)(=[O:22])=[O:23])=[CH:25][CH:26]=1)([CH3:31])([CH3:32])[CH3:33]
ParticipantsConditionsProcedureWorkupSources & evidenceReaction notes

Participants

5

Reactant 3

HCID 168937Lithium hydroxide, monohydrateHCID 218864351,4-Dioxane--water (1/1)HCID 669016926-[(4-tert-Butylphenyl)sulfonyl]-7-methyl-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine-8-carbonitrile

Product 1

HCID 596186196-[(4-tert-Butylphenyl)sulfonyl]-7-methyl-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine-8-carboxamide

Reagents, catalysts & solvents 1

HCID 8857Ethyl AcetateSolvent

Conditions

Temperature
100 °C

Procedure

A mixture of 8-cyano-6-[(4-tert-butylphenyl)sulfonyl]-7-methyl-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine (199 mg, 0.398 mmol) and lithium hydroxide monohydrate (50.1 mg, 2.295 mmol) in 1:1 dioxane-water was heated in a microwave reactor for 15 min at 100° C., followed by 30 min at 120° C. The reaction mixture was cooled to room temperature, diluted with EtOAc, and the organic layer was separated, washed with water, brine, dried over MgSO4 and concentrated. The residue was purified via reverse-phase HPLC to provide the title compound. LC/MS: m/e 519.1 (M+H)+. 1H NMR (500 MHz, CD3OD): δ 7.60 (1H, d), 7.35 (1H, d), 7.15 (2H, d), 7.03-7.10 (3H, m), 6.93 (1H, d), 5.19 (1H, d), 4.40 (1H, d), 2.60 (3H, s), 1.25 (9H, s).

Workup

  1. temperatureThe reaction mixture was cooled to room temperature
  2. customthe organic layer was separated
  3. washwashed with water, brine
  4. dry with materialdried over MgSO4
  5. concentrationconcentrated
  6. customThe residue was purified via reverse-phase HPLC

Sources & evidence

ORD record
ord-a65fcbaff5524da184a02ca947b77e54
Source dataset
uspto-grants-2012_04
DOI
10.6084/m9.figshare.5104873.v1
Patent number
US08153626B2

Reaction notes

On this pageParticipantsConditionsProcedureWorkupSources & evidenceReaction notes